Key result
Systemic administration of HMGB1 fragment significantly preserved left ventricular ejection fraction (41% vs 31%, p=0.0001) and reduced myocardial fibrosis in a hamster model of dilated cardiomyopathy.
Why the study?
It was hypothesized that systemic administration of high-mobility group box 1 fragment attenuates myocardial fibrosis and cardiac dysfunction in dilated cardiomyopathy by recruiting bone marrow mesenchymal stem cells.
Does systemic administration of HMGB1 fragment attenuate the progression of myocardial fibrosis and cardiac dysfunction in a hamster model of dilated cardiomyopathy?
Does systemic administration of HMGB1 fragment attenuate the progression of myocardial fibrosis and cardiac dysfunction in a hamster model of dilated cardiomyopathy?
Systemic administration of HMGB1 fragment attenuates left ventricular remodeling and improves survival in a hamster model of dilated cardiomyopathy by enhancing bone marrow mesenchymal stem cell homing.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for HMGB1 fragment in dilated cardiomyopathy models; leaves open translation to human disease.
OBJECTIVES: We hypothesized that systemic administration of high-mobility group box 1 fragment attenuates the progression of myocardial fibrosis and cardiac dysfunction in a hamster model of dilated cardiomyopathy by recruiting bone marrow mesenchymal stem cells thus causing enhancement of a self-regeneration system. METHODS: Twenty-week-old J2N-k hamsters, which are δ-sarcoglycan-deficient, were treated with systemic injection of high-mobility group box 1 fragment (HMGB1, n = 15) or phosphate buffered saline (control, n = 11). Echocardiography for left ventricular function, cardiac histology, and molecular biology were analyzed. The life-prolonging effect was assessed separately using the HMGB1 and control groups, in addition to a monthly HMGB1 group which received monthly systemic injections of high-mobility group box 1 fragment, 3 times (HMGB1, n = 11, control, n = 9, monthly HMGB1, n = 9). RESULTS: The HMGB1 group showed improved left ventricular ejection fraction, reduced myocardial fibrosis, and increased capillary density. The number of platelet-derived growth factor receptor-alpha and CD106 positive mesenchymal stem cells detected in the myocardium was significantly increased, and intra-myocardial expression of tumor necrosis factor α stimulating gene 6, hepatic growth factor, and vascular endothelial growth factor were significantly upregulated after high-mobility group box 1 fragment administration. Improved survival was observed in the monthly HMGB1 group compared with the control group. CONCLUSIONS: Systemic high-mobility group box 1 fragment administration attenuates the progression of left ventricular remodeling in a hamster model of dilated cardiomyopathy by enhanced homing of bone marrow mesenchymal stem cells into damaged myocardium, suggesting that high-mobility group box 1 fragment could be a new treatment for dilated cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Kido et al. (2018) studied Dilated cardiomyopathy (n=55). High-mobility group box 1 (HMGB1) fragment vs. Phosphate buffered saline (PBS) was evaluated on Left ventricular ejection fraction (LVEF) at 6 weeks (p=0.0001). Systemic administration of HMGB1 fragment significantly preserved left ventricular ejection fraction (41% vs 31%, p=0.0001) and reduced myocardial fibrosis in a hamster model of dilated cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: